A Sequential Dose Cohort Pharmacokinetic and Safety Study of Implantable Long-Acting Naltrexone Subcutaneous Pellets With or Without Bupropion Compared to Naltrexone IM Injection (Vivitrol®) in Healthy Normal Volunteers
Latest Information Update: 19 May 2026
At a glance
- Drugs Bupropion (Primary) ; Naltrexone (Primary) ; Naltrexone
- Indications Alcoholism; Opioid-related disorders; Substance-related disorders
- Focus Pharmacokinetics
- Sponsors BioCorRx Pharmaceuticals
Most Recent Events
- 13 May 2026 Status changed from not yet recruiting to recruiting.
- 11 Dec 2025 New trial record